Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Acro Biomedical (ACBM) Debt to Equity (2016 - 2022)

Acro Biomedical (ACBM) has 7 years of Debt to Equity data on record, last reported at $0.32 in Q4 2022.

  • For Q4 2022, Debt to Equity rose 402.99% year-over-year to $0.32; the TTM value through Dec 2022 reached $0.32, up 402.99%, while the annual FY2022 figure was $0.32, 402.99% up from the prior year.
  • Debt to Equity reached $0.32 in Q4 2022 per ACBM's latest filing, up from $0.16 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.71 in Q4 2020 and bottomed at $0.0 in Q4 2018.
  • Average Debt to Equity over 5 years is $0.15, with a median of $0.09 recorded in 2019.
  • Peak YoY movement for Debt to Equity: plummeted 96.0% in 2018, then surged 2051.95% in 2020.
  • A 5-year view of Debt to Equity shows it stood at $0.0 in 2018, then surged by 1077.2% to $0.03 in 2019, then soared by 2051.95% to $0.71 in 2020, then crashed by 90.9% to $0.06 in 2021, then surged by 402.99% to $0.32 in 2022.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $0.32 in Q4 2022, $0.16 in Q3 2022, and $0.04 in Q2 2022.